## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## LISTING OF CLAIMS:

1. (currently amended) A method for inhibiting vascular endothelial growth factor (VEGF) induced cell proliferation treating a cancer selected from lymphoma in a subject in need thereof, comprising, administering to said subject an effective amount of oxidized adenosine triphosphate (o ATP) adenosine-5'-triphosphate-2',3'-dialdehyde.

## 2-8. (cancelled)

- 9. (currently amended) A method for inhibiting vascular endothelial growth factor (VEGF)-induced cell proliferation of endothelial cells, comprising: administering to said endothelial cells an effective amount of oxidized adenosine triphosphate (o-ATP) adenosine-5'-triphosphate-2',3'-dialdehyde.
- 10. (previously presented) The method according to claim 9, wherein the endothelial cells are human endothelial cells.

Docket No. 2503-1228 Appln. No. 10/589,621

11-13. (cancelled)

14. (currently amended) The method according to claim [[12]] 1, wherein the e-ATP adenosine-5'-triphosphate-2',3'-dialdehyde is administered in [[the]] a pharmaceutical form ef a preparation selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

15. (currently amended) The method according to claim

1, wherein the o ATP adenosine-5'-triphosphate-2',3'-dialdehyde

is administered in a daily dosage of 0.01 to 100 mg per kg of
body weight of said patient.

16-17. (cancelled)